Display options
Cite
Sommer IE, Bearden CE, van Dellen E, et al. Early interventions in risk groups for schizophrenia: what are we waiting for?. NPJ Schizophr. 2016;2:16003doi: 10.1038/npjschz.2016.3.
Sommer, I. E., Bearden, C. E., van Dellen, E., Breetvelt, E. J., Duijff, S. N., Maijer, K., van Amelsvoort, T., de Haan, L., Gur, R. E., Arango, C., Díaz-Caneja, C. M., Vinkers, C. H., & Vorstman, J. A. (2016). Early interventions in risk groups for schizophrenia: what are we waiting for?. NPJ schizophrenia, 216003. https://doi.org/10.1038/npjschz.2016.3
Sommer, Iris E, et al. "Early interventions in risk groups for schizophrenia: what are we waiting for?." NPJ schizophrenia vol. 2 (2016): 16003. doi: https://doi.org/10.1038/npjschz.2016.3
Sommer IE, Bearden CE, van Dellen E, Breetvelt EJ, Duijff SN, Maijer K, van Amelsvoort T, de Haan L, Gur RE, Arango C, Díaz-Caneja CM, Vinkers CH, Vorstman JA. Early interventions in risk groups for schizophrenia: what are we waiting for?. NPJ Schizophr. 2016 Mar 09;2:16003. doi: 10.1038/npjschz.2016.3. eCollection 2016. PMID: 27336054; PMCID: PMC4849435.
Copy Download .nbib Format: NLM
Share it on

NPJ Schizophr. 2016 Mar 09;2:16003. doi: 10.1038/npjschz.2016.3. eCollection 2016.

Early interventions in risk groups for schizophrenia: what are we waiting for?.

NPJ schizophrenia

Iris E Sommer, Carrie E Bearden, Edwin van Dellen, Elemi J Breetvelt, Sasja N Duijff, Kim Maijer, Therese van Amelsvoort, Lieuwe de Haan, Raquel E Gur, Celso Arango, Covadonga M Díaz-Caneja, Christiaan H Vinkers, Jacob As Vorstman

Affiliations

  1. Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht , Utrecht, the Netherlands.
  2. Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences and Psychology, University of California , Los Angeles, CA, USA.
  3. Department of Psychiatry and Psychology, Maastricht University , Maastricht, The Netherlands.
  4. Department of Psychiatry, Academic Psychiatric Centre, AMC , Amsterdam, The Netherlands.
  5. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.
  6. Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, IiSGM, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, School of Medicine, Universidad Complutense , Madrid, Spain.

PMID: 27336054 PMCID: PMC4849435 DOI: 10.1038/npjschz.2016.3

Abstract

Intervention strategies in adolescents at ultra high-risk (UHR) for psychosis are promising for reducing conversion to overt illness, but have only limited impact on functional outcome. Recent studies suggest that cognition does not further decline during the UHR stage. As social and cognitive impairments typically develop before the first psychotic episode and even years before the UHR stage, prevention should also start much earlier in the groups at risk for schizophrenia and other psychiatric disorders. Early intervention strategies could aim to improve stress resilience, optimize brain maturation, and prevent or alleviate adverse environmental circumstances. These strategies should urgently be tested for efficacy: the prevalence of ~1% implies that yearly ~22 in every 100,000 people develop overt symptoms of this illness, despite the fact that for many of them-e.g., children with an affected first-degree family member or carriers of specific genetic variants-increased risk was already identifiable early in life. Our current ability to recognize several risk groups at an early age not only provides an opportunity, but also implies a clinical imperative to act. Time is pressing to investigate preventive interventions in high-risk children to mitigate or prevent the development of schizophrenia and related psychiatric disorders.

References

  1. Lancet Psychiatry. 2015 Jun;2(6):524-31 - PubMed
  2. Schizophr Res. 2012 Apr;136(1-3):13-8 - PubMed
  3. Curr Opin Neurol. 2013 Apr;26(2):128-36 - PubMed
  4. J Clin Psychiatry. 2012 Jun;73(6):e728-34 - PubMed
  5. Schizophr Bull. 2015 Jul;41(4):963-70 - PubMed
  6. J Physiol Biochem. 2015 Jun;71(2):341-9 - PubMed
  7. Schizophr Bull. 2014 Mar;40 Suppl 2:S138-46 - PubMed
  8. Schizophr Bull. 2015 Jul;41(4):801-16 - PubMed
  9. Trends Neurosci. 2002 Jun;25(6):295-301 - PubMed
  10. Schizophr Bull. 2015 Jul;41(4):795-800 - PubMed
  11. Br J Psychiatry. 2012 Jun;200(6):462-8 - PubMed
  12. Front Hum Neurosci. 2014 Sep 15;8:720 - PubMed
  13. Annu Rev Clin Psychol. 2012;8:269-89 - PubMed
  14. Expert Opin Investig Drugs. 2010 Oct;19(10):1217-33 - PubMed
  15. Schizophr Bull. 2010 Jan;36(1):71-93 - PubMed
  16. Arch Gen Psychiatry. 2008 Dec;65(12):1410-8 - PubMed
  17. Schizophr Res. 2010 Oct;123(1):30-6 - PubMed
  18. Front Hum Neurosci. 2014 Aug 13;8:627 - PubMed
  19. Cereb Cortex. 2011 Mar;21(3):574-87 - PubMed
  20. Schizophr Res. 2015 Feb;161(2-3):403-6 - PubMed
  21. J Clin Psychiatry. 2014;75 Suppl 1:15-20 - PubMed
  22. Am J Psychiatry. 2008 May;165(5):579-87 - PubMed
  23. Schizophr Bull. 2014 Nov;40(6):1482-90 - PubMed
  24. Psychoneuroendocrinology. 2013 Nov;38(11):2394-404 - PubMed
  25. J Inherit Metab Dis. 2000 Dec;23(8):847-8 - PubMed
  26. Am J Psychiatry. 2003 Sep;160(9):1580-6 - PubMed
  27. Neuron. 2015 Jun 3;86(5):1203-14 - PubMed
  28. Eur Psychiatry. 2014 May;29(4):259-63 - PubMed
  29. Neuropsychopharmacology. 2009 Feb;34(3):739-46 - PubMed
  30. Schizophr Bull. 2010 Jan;36(1):48-70 - PubMed
  31. Early Interv Psychiatry. 2014 Feb;8(1):32-8 - PubMed
  32. Annu Rev Pharmacol Toxicol. 2014;54:483-507 - PubMed
  33. Clin Schizophr Relat Psychoses. 2014 Jan;7(4):223-30 - PubMed
  34. Can J Psychiatry. 2014 Jan;59(1):5-12 - PubMed
  35. Arch Gen Psychiatry. 1999 Jan;56(1):21-7 - PubMed
  36. Psychopharmacology (Berl). 2014 Sep;231(17):3647-62 - PubMed
  37. Mol Psychiatry. 2015 Oct;20(10):1151-60 - PubMed
  38. Schizophr Bull. 2014 Jan;40(1):28-38 - PubMed
  39. Biomark Insights. 2015 Jun 01;10:47-54 - PubMed
  40. Schizophr Res. 2011 Oct;132(1):1-7 - PubMed
  41. Aust N Z J Psychiatry. 2015 Mar;49(3):207-14 - PubMed
  42. Biol Psychiatry. 2011 Mar 1;69(5):442-9 - PubMed
  43. Subst Abuse Treat Prev Policy. 2014 Jun 18;9:24 - PubMed
  44. Psychoneuroendocrinology. 2013 Sep;38(9):1923-7 - PubMed
  45. Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79 - PubMed
  46. Neuron. 2014 Sep 3;83(5):1073-84 - PubMed
  47. Arch Gen Psychiatry. 2000 Nov;57(11):1053-8 - PubMed
  48. Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):305-14 - PubMed
  49. Psychiatry Clin Neurosci. 2010 Oct;64(5):548-54 - PubMed
  50. J Endocrinol Invest. 2014 Aug;37(8):701-8 - PubMed
  51. Neurosci Biobehav Rev. 2008 Aug;32(6):1136-51 - PubMed
  52. Schizophr Bull. 2007 May;33(3):772-81 - PubMed
  53. Ann Intern Med. 2014 May 6;160(9):612-20 - PubMed
  54. Neuropsychopharmacology. 2015 Jan;40(1):190-206 - PubMed
  55. Psychol Med. 2012 Dec;42(12):2463-74 - PubMed
  56. Schizophr Bull. 2015 May;41(3):604-16 - PubMed
  57. Curr Pharm Des. 2014;20(31):5069-76 - PubMed
  58. Br J Psychiatry. 2014;204:354-60 - PubMed
  59. Biol Psychiatry. 2013 May 15;73(10):951-66 - PubMed
  60. Neuropsychopharmacology. 1999 Aug;21(2):203-10 - PubMed
  61. Behav Cogn Psychother. 2013 Oct;41(5):525-48 - PubMed
  62. Psychol Med. 2012 Jul;42(7):1495-506 - PubMed
  63. Nutr Neurosci. 2016 Nov;19(9):387-395 - PubMed
  64. Schizophr Bull. 2015 Jul;41(4):773-5 - PubMed
  65. Neurosci Biobehav Rev. 2015 Sep;56:241-51 - PubMed
  66. Mol Psychiatry. 2015 Jul;20(7):827-38 - PubMed
  67. Mol Psychiatry. 2015 Feb;20(1):84-97 - PubMed
  68. Early Interv Psychiatry. 2015 Aug 16;:null - PubMed
  69. JAMA Psychiatry. 2013 Oct;70(10):1107-12 - PubMed
  70. Neuropharmacology. 2012 Mar;62(3):1322-31 - PubMed
  71. Psychoneuroendocrinology. 2014 Jan;39:214-24 - PubMed
  72. Brain Res Dev Brain Res. 1999 Dec 10;118(1-2):51-9 - PubMed
  73. Biol Psychiatry. 2015 Jan 15;77(2):147-57 - PubMed
  74. PLoS One. 2014 Feb 03;9(2):e88202 - PubMed
  75. Annu Rev Clin Psychol. 2013;9:435-63 - PubMed
  76. Biol Psychiatry. 2013 Sep 15;74(6):410-7 - PubMed
  77. Prostaglandins Leukot Essent Fatty Acids. 2014 Jan;90(1):1-4 - PubMed
  78. Mol Cell Neurosci. 1999 Jan;13(1):25-39 - PubMed
  79. Schizophr Bull. 2009 May;35(3):549-62 - PubMed
  80. Bioethics. 2015 Oct;29(8):543-56 - PubMed
  81. Schizophr Res. 2015 May;164(1-3):8-14 - PubMed
  82. Schizophr Res. 2010 Aug;121(1-3):125-30 - PubMed
  83. Schizophr Res. 2013 May;146(1-3):79-86 - PubMed
  84. Schizophr Bull. 2015 Jul;41(4):817-23 - PubMed
  85. Biol Psychiatry. 2000 Dec 15;48(12):1121-32 - PubMed
  86. Schizophr Bull. 2014 Jul;40(4):744-55 - PubMed
  87. Proc Natl Acad Sci U S A. 1967 Jul;58(1):199-205 - PubMed
  88. Am J Geriatr Psychiatry. 2013 Mar;21(3):218-30 - PubMed
  89. Hum Mol Genet. 2007 Jan 1;16(1):83-91 - PubMed
  90. Mol Psychiatry. 2016 Mar;21(3):386-93 - PubMed
  91. Schizophr Res. 2016 Sep;176(1):41-51 - PubMed
  92. Schizophr Res. 2013 Oct;150(1):51-7 - PubMed
  93. Psychol Med. 2013 Oct;43(10):2077-86 - PubMed
  94. Biol Psychiatry. 2014 Feb 15;75(4):324-31 - PubMed
  95. Acta Psychiatr Scand. 2014 Jul;130(1):1-15 - PubMed
  96. Antioxid Redox Signal. 2013 Apr 20;18(12):1475-90 - PubMed
  97. Psychol Med. 2011 Mar;41(3):463-76 - PubMed
  98. Psychol Med. 2015 May;45(7):1435-46 - PubMed
  99. Biol Psychiatry. 2013 May 15;73(10):1024-34 - PubMed
  100. PLoS One. 2013;8(1):e53187 - PubMed
  101. Arch Pediatr Adolesc Med. 2012 Feb;166(2):149-56 - PubMed
  102. Brain Res. 1997 Jul 4;761(2):271-82 - PubMed
  103. J Psychopharmacol. 2013 Sep;27(9):761-70 - PubMed
  104. Expert Opin Ther Targets. 2014 Sep;18(9):1049-63 - PubMed
  105. Am J Psychiatry. 2014 Jan;171(1):91-101 - PubMed
  106. Nature. 2004 Jan 22;427(6972):311-2 - PubMed
  107. Mol Psychiatry. 2013 Jan;18(1):10-1 - PubMed
  108. Pediatrics. 2015 Aug;136(2):e539-43 - PubMed
  109. JAMA Psychiatry. 2015 Apr;72(4):377-85 - PubMed
  110. Am J Psychiatry. 2013 Mar;170(3):290-8 - PubMed
  111. Am J Psychiatry. 2013 Jul;170(7):734-41 - PubMed
  112. Br J Psychiatry. 2014 Feb;204(2):108-14 - PubMed
  113. Science. 2006 Dec 8;314(5805):1610-3 - PubMed
  114. Epidemiol Rev. 2008;30:67-76 - PubMed
  115. Curr Pharm Des. 2010;16(5):522-37 - PubMed
  116. Nat Commun. 2015 Aug 11;6:7934 - PubMed
  117. Trends Pharmacol Sci. 2013 Mar;34(3):167-77 - PubMed
  118. Schizophr Bull. 2002;28(3):401-14 - PubMed

Publication Types

Grant support